Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events

被引:70
作者
Mulder, D. J. [1 ]
van Haelst, P. L. [2 ]
Graaff, R. [3 ]
Gans, R. O. [1 ]
Zijlstra, F. [4 ]
Smit, A. J. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9700 RB Groningen, Netherlands
[2] Antonius Hosp, Dept Cardiol, Sneek, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Biomed Engn, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9700 RB Groningen, Netherlands
关键词
myocardial infarction; oxidative stress; inflammation; autofluorescence; advanced glycation endproducts; GLYCATION END-PRODUCTS; CORONARY-ARTERY-DISEASE; EXTRACELLULAR-SUPEROXIDE DISMUTASE; OXIDATIVE STRESS; SERUM-LEVELS; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR EVENTS; SOLUBLE RECEPTOR; HEART-DISEASE; MARKER;
D O I
10.1007/BF03086239
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. ST-elevation myocardial infarction Back, (STEMI) is associated with increased inflammation and oxidative stress, enhancing the formation of advanced glycation endproducts (AGEs). Thew , encompass characteristic fluorescence: pattern, which can be non-invasively measured as skin autofluorescence (AF). In this study we investigate whether skin AF is elevated in STEMI, its association with inflammatory and glycaemic stress,and its predictive value for future events. Methods. Skin AF was measured in 88 STEMI patients (mean age 64 +/- 13 years) within 72 hours and around six months after discharge, in 81 stable coronary artery disease (sCAD) patients (64 +/- 10 years), and in 32 healthy controls (63 +/- 11 years). The cumulative one-year incidence Of all-cause mortality and hospitalisation for myocardial infarction Or heart failure was documented. Results. Skin AF was significantly higher in STEMI compared with sCAD and controls, irrespective of: confounders, and was associated with HbA1c and C-reactive protein. Skin AF decreased significantly in STEMI patients, when measured >200 days after discharge. In STEMI patients, skin AF above g the median was predictive of future events (hazard ratio 11.6, 95% CI 1.5 to 90.8, p=0.019). Conclusion . Skin AF is elevated in STEMI, is associated with inflammation and glycaemic stress, and predicts future major adverse cardiac events. (Neth Heart J 2009;17:162-8.)
引用
收藏
页码:162 / 168
页数:9
相关论文
共 34 条
[1]   Glycoxidation and lipoxidation in atherogenesis [J].
Baynes, JW ;
Thorpe, SR .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 28 (12) :1708-1716
[2]   AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept [J].
Bierhaus, A ;
Hofmann, MA ;
Ziegler, R ;
Nawroth, PP .
CARDIOVASCULAR RESEARCH, 1998, 37 (03) :586-600
[3]   Receptor for advanced-glycation end products - Key modulator of myocardial ischemic injury [J].
Bucciarelli, LG ;
Kaneko, M ;
Ananthakrishnan, R ;
Harja, E ;
Lee, LK ;
Hwang, YC ;
Lerner, S ;
Bakr, S ;
Li, Q ;
Lu, Y ;
Song, F ;
Qu, W ;
Gomez, T ;
Zou, YS ;
Yan, SF ;
Schmidt, AM ;
Ramasamy, R .
CIRCULATION, 2006, 113 (09) :1226-1234
[4]   Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis [J].
Forbes, JM ;
Yee, LTL ;
Thallas, V ;
Lassila, M ;
Candido, R ;
Jandeleit-Dahm, KA ;
Thomas, MC ;
Burns, WC ;
Deemer, EK ;
Thorpe, SM ;
Cooper, ME ;
Allen, TJ .
DIABETES, 2004, 53 (07) :1813-1823
[5]   The advanced glycation end product, N-(epsilon)(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions [J].
Fu, MX ;
Requena, JR ;
Jenkins, AJ ;
Lyons, TJ ;
Baynes, JW ;
Thorpe, SR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (17) :9982-9986
[6]   Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease [J].
Hartog, JWL ;
De Vries, APJ ;
Lutgers, HL ;
Meerwaldt, R ;
Huisman, RM ;
Van Son, WJ ;
De Jong, PE ;
Smit, AJ .
MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE, 2005, 1043 :299-307
[7]   Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease [J].
Heitzer, T ;
Schlinzig, T ;
Krohn, K ;
Meinertz, T ;
Münzel, T .
CIRCULATION, 2001, 104 (22) :2673-2678
[8]   Malondialdehyde-modified LBL as a marker of acute coronary syndromes [J].
Holvoet, P ;
Collen, D ;
Van de Werf, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (18) :1718-1721
[9]   Upregulation of vascular extracellular superoxide dismutase in patients with acute coronary syndromes [J].
Horiuchi, M ;
Tsutsui, M ;
Tasaki, H ;
Morishita, T ;
Suda, O ;
Nakata, S ;
Nihei, S ;
Miyamoto, M ;
Kouzuma, R ;
Okazaki, M ;
Yanagihara, N ;
Adachi, T ;
Nakashima, Y .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (01) :106-111
[10]   Advanced glycation end products in nondiabetic patients with coronary artery disease [J].
Kanauchi, M ;
Tsujimoto, N ;
Hashimoto, T .
DIABETES CARE, 2001, 24 (09) :1620-1623